SillaJen, Inc. (KOSDAQ:215600)

Market Cap	459.28B
Revenue (ttm)	6.37B
Net Income (ttm)	-25.23B
Shares Out	138.13M
EPS (ttm)	-183.63
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,341,634
Average Volume	2,841,963
Open	3,270.00
Previous Close	3,270.00
Day's Range	3,240.00 - 3,395.00
52-Week Range	1,873.00 - 4,700.00
Beta	0.05
RSI	59.03
Earnings Date	Aug 12, 2025

About SillaJen

SillaJen, Inc. develops and commercializes oncolytic immunotherapy products in South Korea. Its lead product is Pexa-Vec for the treatment of solid tumors and induction of cancer specific antibodies. The company also develops BAL0891, a dual TTK/PLK inhibitor; SJ-600 to improve the intravenous administration efficiency of anticancer viruses; JX-970 for the treatment of tumor tissues; and JX-900 is a series of modified vaccinia vaccine. SillaJen, Inc. was founded in 2006 and is headquartered in Seoul, South Korea.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2006
• Employees: 37
• Stock Exchange: KOSDAQ
• Ticker Symbol: 215600

Financial Performance

In 2024, SillaJen's revenue was 3.93 billion, a decrease of -0.33% compared to the previous year's 3.94 billion. Losses were -26.53 billion, 30.2% more than in 2023.